Matthew A. Gubens

Matthew A. Gubens, MD, MS, is Professor of Medicine at the University of California, San Francisco (UCSF), where he serves as Medical Director of Thoracic Medical Oncology and is a key member of the Division of Hematology/Oncology within the Department of Medicine. He is also Chair of the UCSF Cancer Center Protocol Review and Monitoring Committee, overseeing clinical cancer research at the institution.

Education:

• BA in Ethics, Politics and Economics, Yale University (1997)
• MS in Health Policy and Management, Harvard T.H. Chan School of Public Health (2000)
• MD, Stanford University School of Medicine (2005)
• Residency in Internal Medicine, UCSF (2008)
• Fellowship in Medical Oncology, Stanford University (2011)

Dr. Gubens is a nationally recognized thoracic medical oncologist with expertise in non-small cell lung cancer, small cell lung cancer, thymoma, thymic carcinoma, and malignant mesothelioma. His research focuses on advancing precision medicine through biomarker development, immunotherapy optimization, and clinical trial design for thoracic malignancies. He is particularly interested in understanding treatment response and toxicity using genomic and clinical data.

The most recent articles highlight a strong emphasis on immunotherapy (especially immune checkpoint inhibitors), germline and polygenic predictors of toxicity, frailty assessment in older patients, and national guideline development for lung cancer and thymic tumors. His work spans clinical guidelines (NCCN, ASCO, American Radium Society), biomarker-driven trials, and real-world evidence studies.

Scientific Awards and Recognition:

• Fellow of the American Society of Clinical Oncology (FASCO)

Dr. Gubens is actively involved in mentoring and collaborative research. He serves as Immediate Past Chair of the ASCO Evidence-Based Medicine Committee and co-chairs the ASCO Thoracic Guideline Advisory Group. He also contributes to NCCN guideline panels for non-small cell lung cancer, mesothelioma, and thymic malignancies. His leadership extends to the Association of Northern California Oncologists, where he serves on the Board of Directors. He is involved in multiple clinical trials, including those evaluating sotorasib, lazertinib, amivantamab, and neoadjuvant osimertinib.

He is affiliated with the Thoracic Oncology Program and the UCSF Helen Diller Family Comprehensive Cancer Center, working in close collaboration with multidisciplinary teams to advance patient care and research in thoracic malignancies.